New York Methodist Hospital Drug Protocols
|
|
|
- Loreen Warren
- 8 years ago
- Views:
Transcription
1 New York Methodist Hospital Drug Protocols Contributed by Administrator Monday, 05 October 2009 Last Updated Friday, 27 May 2016 NYM Intranet New York Methodist Hospital Drug Protocols are approved by the Pharmacy and Therapeutics Committee. The protocols are also added as reference text in Cerner Millennium and can be accessed from the Medication List using the reference text icon. Pharmacy And Therapeutics Committee Overview 25/09/2014,16:16 Medication Protocols Can Be Accessed via Intranet or via Cerner /10/2015,08:35 A. Concomitant Use Of Antithrombotic Agents Rev /11/2014,12:19 Abciximab_REOPRO 21/03/2011,17:25 Acetaminophen IV (Ofirmev) Protocol /06/2014,15:24
2 Acetylcysteine (Acetadote, NAC) ADULT /04/2016,15:33 Adenosine ADENOCARD 28/03/2011,10:53 Alcohol Withdrawal Protocol /08/2013,13:14 Alteplase Activase Protocol /08/2015,16:25 Alteplase Activase For Periphera Arterial Occlusion Pprotocol /09/2013,12:41 Alteplase Cathflo Activase Intracatheter Injection Protocol 27/08/2015,16:26 Ambrisentan Letairis 22/03/2011,16:42 Amiodarone Cordarone 22/03/2011,16:49 Ampicillin 22/03/2011,16:50 Antibiotic_Orderset_Final_Combined_9.2011_Formulary_Change_To_Mero 31/10/2011,16:33 ApixabanEliquis Protocol /10/2014,13:39 Argatroban_Protocol 12/06/2015,15:15 Artesunate_Protocol /10/2011,16:34
3 B. Baclofen Lioresal 22/03/2011,16:52 Bioterrorism Protocols 22/03/2011,17:01 Bivalirudin Angiomax 22/03/2011,16:53 Blood Factor Reference Card rev /05/2016,15:13 Bretylol 22/03/2011,16:54 Bumetanide (Bumex) Protocol rev /10/2015,16:00 C. Carboplatin Protocol rev_ /03/2015,15:17
4 Candidurea Bladder Infection And Colonization 22/03/2011,17:03 Central Line Medication Administration Protocol_rev_ /03/2015,15:20 Cervical Ripening Protocol 22/03/2011,17:05 Chemoembolization Preparation 22/03/2011,17:06 Cisatracurium Protocol /09/2015,16:34 Clevidipine (Cleviprex) /09/2015,16:40 Clopidogrel Plavix Protocol 27/08/2015,16:28 Cangrelor (Kengreal) Protocol /02/2016,11:02 Conivaptan Vaprisol 22/03/2011,17:08 Continuous Drips For Stepdown Units Rev /05/2016,15:17 Contrast_Media_Iodine_Protocol 31/10/2011,16:32
5 D. Dabigatran Protocol /05/2016,15:08 Dantrolene Protocol Final April /04/2013,09:14 Darbepoetin Aranesp /04/2016,15:31 Desensitization protocols 22/03/2011,17:26 Dexmedetomidine Precedex /09/2015,16:41 Dextrose 50 22/03/2011,17:27 Diazepam Valium 22/03/2011,17:27 Digoxin 22/03/2011,17:28 Digoxin Immune Fab Digibind 22/03/2011,17:30 Diltiazem Protocol 8_ /09/2015,16:43 Diphenhydramine BENADRYL 28/03/2011,10:50 Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine 22/03/2011,17:33
6 Drug Extravasation Protocol Rev /10/2014,15:04 Dobutamine Protocol /09/2015,16:46 Dopamine /09/2015,16:47 Do Not Crush List /01/2014,13:21 E. Edoxaban Savaysa Protocol 06/07/2015,12:31 Elective Colorectal Cancer Order Set 22/03/2011,17:44 Enoxaparin Lovenox Protocol /02/2016,12:02 Enteral Tube Feed Medication Guide /04/2014,17:18 Entresto Protocol 05/04/2016,16:30
7 Epinephrine /09/2015,16:48 Epoetin Alfa PROCRIT 22/03/2011,17:47 Epoprostenol Flolan 22/03/2011,17:48 Eptifibatide INTEGRILIN 22/03/2011,17:49 Esmolol Protocol /09/2015,16:49 Esomeprazole NEXIUM 22/03/2011,17:50 Exparelin TKA Jan /01/2014,13:26 Ezetimibe Simvastatin VYTORIN 22/03/2011,17:51 F. Factor VIIA Protocol 08_17_ /10/2013,16:45 Feiba Protocol /05/2016,15:14
8 Fentanyl Adult ICU Protocol 11/09/2015,16:51 Fentanyl Protocol 01/07/2015,11:19 Fondaparinux ARIXTRA 22/03/2011,17:54 Fosphenytoin CEREBYX 22/03/2011,17:55 Furosemide (Lasix) Protocol rev /10/2015,16:01 G. Gamunex Immune Globulin (IVIg) ADULT Protocol 04/03/2014,12:40 Gamunex Immune Globulin (IVIg) PEDIATRIC Protocol 04/03/2014,12:43 H.
9 Haldol Protocol rev_2_27_15 09/03/2015,17:13 Heparin ACS Protocol /09/2013,13:29 Heparin DVT PE Protocol /09/2013,13:30 Heparin Ischemic Stroke Protocoll 22/03/2011,18:06 Hydralazine APRESOLINE 22/03/2011,18:06 Hydromorphone Adult ICU Protocol 11/09/2015,16:54 Hydromorphone_Protocol 11/06/2015,16:54 Hyperkalemia Protocol 22/03/2011,18:17 Hypoglycemia Protocol 22/03/2011,18:18 Hyperthermia Protocol April 13 25/04/2013,09:17 I.
10 Ibuprofen IV NEOPROFEN IV 23/03/2011,09:33 Ibutilide CORVERT 23/03/2011,09:36 Idarucizumab (Paxbind) Protocol /02/2016,11:06 Inhaled Antibiotics Protocol 23/03/2011,09:40 Insomnia Protocol 23/03/2011,09:41 Insulin Protocol Non DKA And Honk-ccapp 22/04/2015,15:07 NYMH Pharmacokinetics of Formulary Insulin Preparations 22/11/2011,16:11 Intervention Radiology Protocol 23/03/2011,09:43 Intrapleural Fibrinolytics TPA Pulmozyme Protocol /05/2016,15:18 Intranasal Medication Administration Protocol 03/08/2015,15:23 Iron Dextran (INFed) Injection Protocol 13/05/2014,13:35 Iron Sucrose (Venofer) Intravenous Injection Protocol 13/05/2014,13:36 IV Push Medications with parameters Critical Care areas 06/10/2015,12:11
11 IV Push Medications With parameters Step Down Units 10/08/2015,14:45 IV Push Medications INF /01/2016,14:37 IV Push Med Surge Floors 06/10/2015,11:44 J. K. Kayexalate Enema Protocol rev_ /03/2015,17:06 Ketamine_Protocol 11/06/2015,16:39 Ketorolac PO-IV-IM Protocol Revised /05/2014,13:38
12 L. Labetalol (Trandate) /09/2015,16:56 Lansoprazole ORAL PREVACID 23/03/2011,09:56 Lithium Monitoring Guidelines 23/03/2011,09:58 Lorazepam Ativan 23/03/2011,09:59 Lorazepam Protocol /09/2015,16:57 M. Mannitol 23/03/2011,10:01 Meperidine_Protocol 11/06/2015,16:46 Metoprolol_Monograph_ 03/11/2011,09:19
13 Micafungin MYCAMINE 23/03/2011,10:02 Midazolam Protocol /09/2015,16:58 Milrinone Protocol 02/10/2015,14:45 Misoprostol Cytotec 23/03/2011,10:03 Morphine Adult 30/05/2012,16:48 Morphine for Adult ICU Protocol 11/09/2015,17:00 Morphine Palliative Care 26/06/2014,12:53 Morphine Peds 30/05/2012,16:49 N. Naloxone Protocol rev_ /03/2015,17:16 Natalizumab TYSABRI Dispensing Process 23/03/2011,10:05
14 Nexium_Protocol 11/06/2015,16:41 Nicardipine Cardene Protocol 08/07/2014,16:16 Nitroglycerin Protocol 04/02/2016,11:50 Norepinephrine Protocol /09/2015,17:01 Neonatal Protocols Neonatal_Alprostadil 11/09/2015,14:52 Neonatal Continuous Infusion Titratable 11/09/2015,14:58 Neonatal Dobutamine 11/09/2015,15:09 Neonatal Dopamine 11/09/2015,15:10 Neonatal Epinephrine 11/09/2015,15:12 Neonatal Fentanyl 11/09/2015,15:13
15 Neonatal Furosemide 11/09/2015,15:14 Neonatal Insulin 11/09/2015,15:15 Neonatal Isoproterenol 11/09/2015,15:16 Neonatal Milrinone 11/09/2015,15:16 Neonatal Morphine 11/09/2015,15:17 Neonatal Sodium Bicarbonate 11/09/2015,15:19 O. Octreotide Sandostatin Final Protocol April 13 25/04/2013,09:27 Omegaven Protocol_ /10/2014,13:33
16 P. Pain Management Order Set For Elderly Renal Insufficiency Cardio 05/04/2016,16:31 Pain Management Power Plan general with opioids #1 27/03/2015,15:46 Pain Management Power Plan General No Opioids #2 27/03/2015,15:38 Pain Management Powerplan General 25/06/2014,15:32 Pain Management Power Plan Pediatrics 29/10/2015,12:23 Pantoprazole PROTONIX 23/03/2011,10:14 Peramivir 23/03/2011,12:39 Percutaneous Coronary Intervention Pci Pathway 23/03/2011,12:41 Phenobarbital IV Luminal 23/03/2011,12:43 Phenylephrine Protocol /09/2015,17:02 Phenytoin Sodium Dilantin 23/03/2011,12:46
17 Phytonadione /04/2016,16:35 Piperacillin-Tazobactam_zosyn 23/03/2011,12:47 Post Exposure Prophylaxis 23/03/2011,12:49 Potassium Chloride Protocol rev_ /03/2015,15:12 Preemptive Analgesia 23/03/2011,12:50 Profilnine Protocol 18/04/2016,14:57 Profilnine Protocol Final 29/10/2015,12:25 Propofol /09/2015,17:05 Propofol Diprivan 23/03/2011,12:50 Propofol Propoven 23/03/2011,12:51 Protamine 23/03/2011,12:54 Proton Pump Inhibitor (PPI) 23/03/2011,12:55
18 Q. R. Rasburicase 10/08/2015,14:41 Recombinate Recombinant Antihemophilic Factor Rev /05/2016,15:19 Regadenoson Lexisca 23/03/2011,13:01 Remodulin Protocol rev /12/2015,10:36 RenalBook 23/03/2011,13:03 Riociguat (Adempas) Protocol final /08/2015,16:34 Rivaroxaban Xarelto Protocol /10/2014,13:42 Rocuronium Protocol /09/2015,17:06 S.
19 Sitagliptin Januvia 23/03/2011,13:00 SCIP_Post_Operative_Protocol_ 03/11/2011,09:17 Sodium Bicarbonate IV Protocol 03/03/2014,12:26 Sodium Nitroprusside /09/2015,17:07 T. Thrombolytics in Pulmonary Embolism 23/03/2011,13:04 Tolvaptan Samsca Protocol Rev /08/2015,16:36 Tranexamic Acid Protocol Rev_ /04/2015,11:30 Ticagrelor Brilinta Protocol /12/2015,09:27 Titratables /09/2015,17:08
20 U. Unfractionated Heparin Order Sheets 23/03/2011,13:08 V. Valproate Epilepsy Guidelines For Psychiatry 23/03/2011,13:09 Valproate Sodium DEPACON 23/03/2011,13:10 Vasopressin Protocol /06/2014,11:40 Vitamin K Phytonadione Protocol /07/2013,11:56 W.
21 Warfarin Protocol 02/10/2013,09:20 Wilate Protocol Rev /01/2016,16:38 X. Y. Z. NYM Intranet
MEDICATION MANUAL Policy & Procedure
MEDICATION MANUAL Policy & Procedure TITLE: High Alert Medication NUMBER: MM 50-010 Effective Date: September 13, 2013 Page 1 of 6 Applies To: Holders of Medication Manual This policy is applicable to
NOTICES. Approved and Required Medications Lists for Emergency Medical Services Agencies and Emergency Medical Services Providers
NOTICES Approved and Required Medications Lists for Emergency Medical Services Agencies and Emergency Medical Services Providers [45 Pa.B. 5451] [Saturday, August 29, 2015] Under 28 Pa. Code 1027.3(c)
Emergency Medications Approved for Use at VAPAHCS
Table 1: Medications (PAD GM&S) Emergency Medications Approved for Use at VAPAHCS PAD GM&S (See HCSM 11-12-35 Attachment A CPR Committee Atropine 1mg/10ml syringe X 3 Normal saline 1000ml bag X 2 Sodium
NOTICES DEPARTMENT OF HEALTH
NOTICES DEPARTMENT OF HEALTH Approved Drugs for ALS Ambulance Services [43 Pa.B. 3060] [Saturday, June 1, 2013] Under 28 Pa. Code 1005.11 (relating to drug use, control and security), the following drugs
North Carolina Medical Board Approved Medications for Credentialed EMS Personnel
North Carolina Medical Board Approved Medications for Credentialed EMS Personnel EMS personnel at any level who administer medications must do so within an EMS system that provides medical oversight. Personnel
Union EMS Local Formulary July 18, 2014
July 18, 2014 Forward The intent of the Union EMS Local Formulary is to provide guidance during the implementation and use of the 2012 NCCEP Protocols, Policies and Procedures to the ALS and BLS Professionals
An introduction to High Risk Medications
An introduction to High Risk Medications Une politique sure des médicaments : déjà deux approches 25 octobre 2013 Danguy Christine Hôpital A. Vésale An introduction to High Risk Medications 1. High Risk
I.V. ADMINISTRATION GUIDELINES All IV meds must be administered by IV pump. Diluent Amount Over (min.) NO D5W 200mL. 500ml. 1000ml.
I.V. ADMINISTRATION GUIDELINES All IV meds must be administered by IV pump Medication Dose Push Acetadote Patients greater than 40 kg Loading Dose: Dose 2: Dose 3: Please use the Online calculator: http://aceta
EMS System for Metropolitan Oklahoma City and Tulsa 2015 Medical Control Board Treatment Protocols
14I INTERHOSPITAL TRANSFERS EMERGENCY MEDICAL DISPATCHER EMERGENCY MEDICAL RESPONDER EMT EMT-INTERMEDIATE 85 ADVANCED EMT PARAMEDIC A patient may require a transfer from one hospital to another hospital
Critical Care/ Emergency Department Medication Competency Exam
Employee name: Score: / = % Critical Care/ Emergency Department Medication Competency Exam Please circle or write in (where applicable) the correct answer for each question below. There is only 1 correct
Anticoagulation and Reversal
Anticoagulation and Reversal John Howard, PharmD, BCPS Clinical Pharmacist Internal Medicine Affiliate Associate Clinical Professor South Carolina College of Pharmacy Disclosures I have no Financial, Industry,
LAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options
LAMC Reversal Agent Guideline for Anticoagulants 2013 Medication resolution of hemostasis (hrs) Intervention Administration Instructions Heparin 3-4 Protamine 1mg IV for every 100 units of heparin Slow
Acetylcysteine Inhalation Solution
Drug Shortage information Action Plan delays and another manufacturer voluntarily suspending production. Hospira has a limited supply available and other manufacturers are unable to estimate a release
Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD
Update on Antiplatelets and anticoagulants Timir Paul, MD, PhD Antiplatelets Indications Doses Long term use (beyond 12 months) ASA and combination use of NSAIDS ASA resistance Plavix resistance Plavix
Authorized Procedure List
Agency Name: Authorized Procedure List Agency Director Signature: Medical Director Signature: Airway Airway Assessment Oxygen Therapy--Nasal Cannula Oxygen Therapy--Non Rebreather Mask Oxygen Therapy-Partial
Inter-facility Patient Transfers
Date: September 2004 Page 1 of 6 Inter-facility Patient Transfers Purpose: The purpose of this policy is to establish a uniform procedure for inter-facility transfers. 1. Responsibility: a. Patient transfer
ADENOSINE (Adenocard) Intermediate- CALL IN Paramedic. ALBUTEROL SULFATE Basic-CALL IN Intermediate-CALL IN Paramedic
ADENOSINE (Adenocard) - CALL IN ALBUTEROL SULFATE Basic-CALL IN AMIODARONE (Cordarone) - CALL IN except in cardiac arrest- call while ASPIRIN Basic ATROPINE SULFATE - CALL IN except in cardiac arrest-
Basic Medication Administration Exam RN (BMAE-RN) Study Guide
Basic Medication Administration Exam RN (BMAE-RN) Study Guide Review correct procedure and precautions for the following routes of administration: Ear drops Enteral feeding tube Eye drops IM, subcut injections
Rivaroxaban (Xarelto ) by
Essentia Health Med Moment Short Video Tune-Up A brief overview of a new medication, or important new medication information Rivaroxaban (Xarelto ) by Richard Mullvain RPH BCPS (AQC) Current - August 2011
Filtration Guidelines for the Administration of Intravenous Medications UK Pharmacy Services Revised 8/2010
iltration Guidelines for the Administration of Intravenous Medications UK Pharmacy Services Revised 8/2010 SUMMARY O CHANGES: Green = Added from literature (Lexi-Comp, Micromedex, pkg inserts) Yellow =
Acute Myocardial Infarction (the formulary thrombolytic for AMI at AAMC is TNK, please see the TNK monograph in this manual for information)
ANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY Guidelines for Use of Intravenous Alteplase (Tissue Plasminogen Activator (t-pa)), Activase in the Treatment
Calculations Practice Problems
Calculations Practice Problems Note: A variety of types of problems are provided for practice. Not all situations will be encountered in all states, depending on state limitations to LPN/LVN practice.
EMMC Guide on Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults. February, 2013
EMMC Guide on Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults February, 2013 1 Quick Index To Reversal Recommendations Anti-Platelet Medications Page P2Y12
Critical Bleeding Reversal Protocol
Critical Bleeding Reversal Protocol Coagulopathy, either drug related or multifactorial, is a major contributing factor to bleeding related mortality in a variety of clinical settings. Standard therapy
Drug List. Medication Adult Dosing Pediatric Dosing. V-fib / pulseless V-tach 300 mg IV push Repeat dose of 150 mg IV push for recurrent episodes
Acetaminophen (Tylenol) 7-Pain Control-Adult 46-Pain Control-Pediatric 72-Fever 1000 mg po 15 mg/kg po Indicated for pain and fever control Avoid in patients with severe liver disease Adenosine (Adenocard)
Basic Medication Administration Exam LPN/LVN (BMAE-LPN/LVN) Study Guide
Basic Medication Administration Exam LPN/LVN (BMAE-LPN/LVN) Study Guide Review correct procedure and precautions for the following routes of administration: Ear drops Enteral feeding tube Eye drops IM,
New Oral Anticoagulants Markets
Brochure More information from http://www.researchandmarkets.com/reports/2497048/ New Oral Anticoagulants Markets Description: Anticoagulants decrease the ability of the blood to create harmful blood clots
ANESTHESIA ASSISTANT (Approved by the College of Physicians and Surgeons of Manitoba, July 2006)
ANESTHESIA ASSISTANT (Approved by the College of Physicians and Surgeons of Manitoba, July 2006) Description of the Position Anesthesia Assistants are allied heath professionals, qualified by advanced
QUICK REFERENCE. Mary Cushman 1 Wendy Lim 2 Neil A Zakai 1. University of Vermont 2. McMaster University
QUICK REFERENCE Clinical Practice Guide on Antithrombotic Drug Dosing and Management of Antithrombotic Drug- Associated Bleeding Complications in Adults February 2014* Mary Cushman 1 Wendy Lim 2 Neil A
Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know. Ronald Walsh, MD Chief Medical Officer Community Blood Services
Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know Ronald Walsh, MD Chief Medical Officer Community Blood Services HEMOSTATIC PROCESS Initiation and formation of the platelet plug
The Brave New (Anticoagulant) World
The Brave New (Anticoagulant) World Diane M. Birnbaumer, M.D., FACEP Emeritus Professor of Medicine University of California, Los Angeles Senior Clinical Educator Department of Emergency Medicine Harbor-UCLA
Cardiology Medications New Drugs, New Guidelines
Cardiology Medications New Drugs, New Guidelines Ken Kester, PharmD, JD Pharmacy Team Leader Nebraska Heart Hospital August 4, 2014 Cardiology Medications Objectives The attendee will understand Indications,
PREPARATIONS: Adrenaline 1mg in 1ml (1:1000) Adrenaline 100micrograms in 1ml (1:10,000)
ADRENALINE Acute hypotension Via a CENTRAL venous line Initially 100-300 nanograms/kg/minute 0.1-0.3 microgram/kg/minute adjusted according to response up to a maximum of 1.5 micrograms/kg/minute. Increase
Anticoagulant therapy
Anticoagulation: The risks Anticoagulant therapy 1990 2002: 600 incidents reported 120 resulted in death of patient 92 deaths related to warfarin usage 28 reports related to heparin usage Incidents in
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults
Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults Purpose: To be used as a common tool for all practitioners involved in the care of patients
Alla chme nl A EFFECTIVE 07/01/2014 BUREAU FOR MEDICAL SERVICES WEST VIRGINIA MEDICAID PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA
A. Re-Review 1. Bethkis ANTIBIOTICS, INHALED BETHKIS (tobramycin) TOBI (tobramycin) 2. Effient CAYSTON (aztreonam) TOBI POOHALER tobramycin PLATELET AGGREGATION INHIBITORS AGGRENOX (dipyridamole/asa) BRIUNTA
for Extended Stability Parenteral Drugs Third Edition Caryn M. Bing, R.Ph., M.S., FASHP Editor
Extended Stability for Parenteral Drugs Third Edition Editor Caryn M. Bing, R.Ph., M.S., FASHP 1 American Society of Health-System Pharmacists Bethesda, Maryland Contents Preface Acknowledgments x/ Dedication
Adult Drug Reference. Dopamine Drip Chart. Pediatric Drug Reference. Pediatric Drug Dosage Charts DRUG REFERENCES
Adult Drug Reference Dopamine Drip Chart Pediatric Drug Reference Pediatric Drug Dosage Charts DRUG REFERENCES ADULT DRUG REFERENCE Drug Indication Adult Dosage Precautions / Comments ADENOSINE Paroxysmal
Objectives. Fluids. Sterile IV Techniques. How many of you have sterile compounding technique procedures at your institution?
Objectives Intravenous Medications in the Intensive Care Unit Paul Juang, Pharm.D., BCPS Assistant Professor of Pharmacy Practice St. Louis College of Pharmacy April 16, 2011 The speaker has no conflict
Cardiology Medications New Drugs, New Guidelines
Cardiology Medications New Drugs, New Guidelines Ken Kester, PharmD, JD Pharmacy Team Leader Nebraska Heart Hospital August 4, 2014 CARDIOLOGY MEDICATIONS Objectives The attendee will understand Indications,
Upstate University Health System Medication Exam - Version A
Upstate University Health System Medication Exam - Version A Name: ID Number: Date: Unit: Directions: Please read each question below. Choose the best response for each of the Multiple Choice and Medication
Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia
Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia Insertion, removal or presence of a catheter in selected sites can place a patient who is antithrombotic agent at risk for a local bleeding
ARTICLE 4.03 AMBULANCE SERVICE* Division 1. Generally
ARTICLE 4.03 AMBULANCE SERVICE* Division 1. Generally Sec. 4.03.001 Penalty for violation Any person violating the provisions of this article shall be punished as provided in section 1.01.009. Sec. 4.03.002
ADULT INTRAVENOUS MEDICATIONS
MEDICATION Adenosine (Adenocard ) Slows conduction time through the AV node, interrupting the re- entry pathways through the AV node, restoring normal sinus rhythm. Onset of action: immediate Duration:
PHARMACOLOGY UPDATE: BOOMER DRUGS
PHARMACOLOGY UPDATE: BOOMER DRUGS Sandra Brownstein, PharmD Evercare Clinical Pharmacy Director West Region Objectives: Review the new drugs that have recently been approved by the FDA Determine the role
Section 700.00: Memorandum Indicating Change or Clarification
700.00: Memorandum Indicating Change or Clarification Memorandums contained in this section are intended to alter or clarify current Volusia County Prehospital Standing Orders and Treatment Protocols.
Disclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU
New Agents for Treatment of DVT Disclosure PI Adopt and Amplify trials Mark Oliver, MD, RVT, RPVI,FSVU BMS and Pfizer Speaker VTE Venous Thromboembolism Recognized DVT s New : 170,000 Recurrent : 90,000
2.5mg SC daily. INR target 2-3 30 mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.
Anticoagulation dosing at UCDMC (SC=subcutaneously; CI=continuous infusion) Indication Agent Dose Comments Prophylaxis Any or No bleeding risk factors see adult heparin (VTE prophylaxis) IV infusion order
Anticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h
Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h See EMR adult VTE prophylaxis CI order set Enoxaparin See service specific dosing Assess
New Anticoagulants: What to Use What to Avoid
New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA
Management for Deep Vein Thrombosis and New Agents
Management for Deep Vein Thrombosis and New Agents Mark Malesker, Pharm.D., FCCP, FCCP, FASHP, BCPS Professor of Pharmacy Practice and Medicine Creighton University 5 th Annual Creighton Cardiovascular
Disclosure/Conflict of Interest
NEW ORAL ANTICOAGULANTS: WHAT EVERY PHARMACIST SHOULD KNOW LORI B. HORNSBY, PHARMD, BCPS ASSOCIATE CLINICAL PROFESSOR AUHSOP CLINICAL PHARMACIST MIDTOWN MEDICAL CENTER OUTPATIENT CLINIC COLUMBUS, GEORGIA
What You Need to Know About Your Nephrostomy Tube
What You Need to Know About Your Nephrostomy Tube Information for patients and families UHN Read this information to learn about: what a nephrostomy tube is and why you may need one how to prepare for
Special Types of Intravenous Calculations
Predham_CH09_F 7/3/09 5:43 PM Page 3 LEARNING OBJECTIVES. Amount of drug in a solution. Rules and calculations for special CHAPTER 9 Special Types of Intravenous Calculations IV orders 3. Units/hr, mg/hr,
48 th Annual Meeting. Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding. Terminology. Disclosure. Public Health Impact.
48 th Annual Meeting Terminology Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding Stacy A. Voils, PharmD, MS, BCPS Navigating the Oceans of Opportunity Target-specific oral anticoagulants
Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab
Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 28, 2015 2:30 pm I have no disclosures. Stroke risk reduction in
PROFESSIONAL BOARD FOR EMERGENCY CARE
PROFESSIONAL BOARD FOR EMERGENCY CARE IMPORTANT NOTICE TO ALL EMERGENCY CARE PRACTITIONERS INTRODUCTION OF NEW SCOPE OF PRACTICE FOR REGISTERED EMERGENCY CARE PRACTITIONERS NOVEMBER 2009 Herewith the July
Medication Calculation Practice Problems
1 Medication Calculation Practice Problems Dosage Calculation 1. The order is for 60 mg of furosemide (Lasix) po daily. Available to the nurse is Lasix 40 mg/tablet. The nurse would administer how many
SCRN Medication Review. Susan M. Gaunt MS APRN ACNS-BC CCRN CNRN Gwinnett Medical Center
SCRN Medication Review Susan M. Gaunt MS APRN ACNS-BC CCRN CNRN Gwinnett Medical Center Objectives To explain the indications, contraindications, interaction, timing, dosing, side effects of: Thrombolytics
More information for patients and caregivers can be accessed at http://www.xarelto-us.com/.
Janssen Research & Development Submits Application to U.S. FDA for XARELTO (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome RARITAN, DECEMBER 29, 2011 -
Appendix 4: Guidelines for Prescribing and Administering Drugs:
Appendix 4: Guidelines for Prescribing and Administering Drugs: A midwife may prescribe and administer the following substances in accordance with the guidelines approved by the Board. This list indicates
Pocket Reference for ICU Staff
Pocket Reference for ICU Staff Information in this booklet should be used as a guide only. The prescriber is responsible for the verification of indications and dosages listed in the manufacturers' package
Time of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
Intravenous Push (IVP) Drug List Approved for RN Administration
Acute Care 1111Page Floor Nurses 1 of 8 Guide: Bumetanide (Bumex) - Diuretic/Acute Pulmonary Edema, CHF, and Renal disease 0.5-2 mg over 1-2 RATE 10 mg/day 0.25 mg/ml 2 mg over 2 Pain at injection Site
New Developments in Neuraxial Anesthesia
New Developments in Neuraxial Anesthesia Vanny Le, MD Assistant Professor Anesthesiology and Pain Management Department of Anesthesiology Rutgers New Jersey Medical School Disclosures No conflicts of interest
Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
Managing Anticoagulants, Antiplatelets, and NSAIDS in the Interventional Radiology Setting. Amy Huggins, BSN, RN
Managing Anticoagulants, Antiplatelets, and NSAIDS in the Interventional Radiology Setting Amy Huggins, BSN, RN Objectives 1 2 3 4 5 Recognize bleeding risk based on classes of IR procedures Differentiate
Management of Patients on Anticoagulants. Haemostasis. Coagulation cascade. Cell-based model 19/11/2013
Management of Patients on Anticoagulants National Coal Mining Museum 11 Nov 2013 Navneet Lad StR Special Care Dentistry Aims: Discuss the different anti-platelet drugs available. Discuss the new generation
To aid practitioners in prescribing unfractionated heparin and low-molecular-weight heparins to patients.
UNFRACTIONATED HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To aid practitioners in prescribing unfractionated heparin and low-molecular-weight
TSOAC Initiation Checklist
Task Establish appropriate dose based on anticoagulant selected, indication and patient factors such as renal function. Evaluate for medication interactions that may necessitate TSOAC dose adjustment.
Jeopardy Topics: THE CLOT STOPS HERE (anticoagulants) SUGAR, SUGAR, HOW D YOU GET SO HIGH (insulins)
Jeopardy Topics: THE CLOT STOPS HERE (anticoagulants) SUGAR, SUGAR, HOW D YOU GET SO HIGH (insulins) I HEAR YA KNOCKING BUT YOU CAN T COME IN (electrolytes) TAKE MY BREATH AWAY (Opiates-morphine) OUT WITH
Palliative Care Drug Plan (Plan P) Formulary List of drugs PharmaCare covers
Palliative Care Drug Plan (Plan P) Formulary List of drugs PharmaCare covers Important Notes: Last Updated: May 11, 2015 Pharmacists must submit a claim on PharmaNet at the time of purchase to enable coverage.
Prostate Assessment Pathway Prostate Biopsy Alerts
Prostate Assessment Pathway Prostate Biopsy Alerts Guidelines for the Management of Patient Preparation, Medications and Complications July 2015 Table of Contents Roles and Responsibilities. 1 SECTION
table of contents drug reference
table of contents drug reference ADULT DRUG REFERENCE...155 161 PEDIATRIC DRUG REFERENCE...162 164 PEDIATRIC WEIGHT-BASED DOSING CHARTS...165 180 Adenosine...165 Amiodarone...166 Atropine...167 Defibrillation...168
Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:
Sudden dizziness, trouble walking, loss of balance or coordination
rivaroxaban (Xarelto) Patient Education Information Sheet Veterans Health System Pharmacy Service 119 What is rivaroxaban (Xarelto)? A new anticoagulant ( blood thinner ) that reduces the risk of stroke
New Oral Anticoagulant (Rivaroxaban [Xarelto])
![New Oral Anticoagulant (Rivaroxaban [Xarelto])](/thumbs/22/1750345.jpg "New Oral Anticoagulant (Rivaroxaban [Xarelto])")
TABLE OF CONTENTS New Oral Anticoagulant (Rivaroxaban [Xarelto]) 1-2 New Antiplatelet (Ticagrelor [Brilinta]) 2-3 Update on Dabigatran (Pradaxa) Safety and Use at UIMCC 3-4 What Methods are Available for
Anticoagulation Therapy Update
Anticoagulation Therapy Update JUDY R. WALLING, FNP-BC ARRHYTHMIA MANAGEMENT MUSC CARDIOLOGY Outline Who do we anticoagulate? Review classes of Anticoagulants Review examples of Anticoagulants Review CHADS2
East Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
Clinical Assistant Professor University of Kansas School of Pharmacy. Objectives
New Oral Anticoagulants Tiffany R. Shin, PharmD, BCACP Clinical Assistant Professor University of Kansas School of Pharmacy 1 Objectives Discuss the advantages and disadvantages of the new oral anticoagulants
New Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
Anticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk
Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart
5/21/2012. JCAHO National Patient Safety Goal: Maintain and communicate accurate patient medication information.
Is 3 rd leading cause of patient harm Medical errors - 8 th leading cause of death in the US Each year in the US, est. 450,000000 preventable med-related adverse events occur 20% of patients have complications
ACLS PHARMACOLOGY 2011 Guidelines
ACLS PHARMACOLOGY 2011 Guidelines ADENOSINE Narrow complex tachycardias or wide complex tachycardias that may be supraventricular in nature. It is effective in treating 90% of the reentry arrhythmias.
News Release. Media contacts: Ernie Knewitz Tel: 908.927.2953 Mobile: 917.697.2318 eknewitz@its.jnj.com
News Release Media contacts: Ernie Knewitz Tel: 908.927.2953 Mobile: 917.697.2318 eknewitz@its.jnj.com Shaun Mickus Phone: 908.927.2416 Mobile: 973.476.7144 smickus@its.jnj.com Investor contacts: Stan
Consultant s Playbook
Consultant s Playbook A Survey of Pharmacy Consultant Experiences Among Hospitals In the University HealthSystem Consortium Dave Hicks, RPh, MBA; Bryan McCarthy, Jr., PharmD, MS, BCPS; John Fanikos, MBA,
How to Use EMERGENCY DRUG TRACKER. Place in a 3 ring binder or clipboard and keep with your emergency drug kit.
How to Use EMERGENCY DRUG TRACKER Place in a 3 ring binder or clipboard and keep with your emergency drug kit. 1. Fill in the circle that contains the month and year your emergency drug expires. 2. This
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
How To Compare The New Oral Anticoagulants
Disclosures The New Oral Anticoagulants: Are they better than Warfarin? Alan P. Agins, Ph.D. does not have any actual or potential conflicts of interest in relation to this CE activity. Alan Agins, Ph.D.
Program Objectives. Why Use Anticoagulants? 6/5/2014
Larry Reis RPh CGP FASCP Prepared June 2014 for NADONA REIS RXCARE CONSULTING Reisrxcare@comcast.net 1 Program Objectives Discuss complications of current anticoagulant Rx Identify risks of using anticoagulants
DABIGATRAN ETEXILATE TARGET Vitamin K epoxide reductase WARFARIN RIVAROXABAN APIXABAN
TARGET SPECIFIC ORAL ANTICOAGULANTS (TSOACs) This document is intended as a guideline only and should not replace sound clinical judgment Please refer to UNMH formulary in Lexicomp for approved use(s)
Emergency Medical Services Advanced Level Competency Checklist
Emergency Services Advanced Level Competency Checklist EMS Service: Current License in State of Nebraska: # (Copy of license kept in file at station) Date of joining EMS Service: EMS Service Member Name:
VUMC INTRAVENOUS MEDICATION ADMINISTRATION CHART
* Refer to references such as Mosby s for additional information on administration and monitoring. Alternate infusion rates permitted at provider discretion. ** Central Line Preferred indicates that the
Practical Management of Patients receiving Rivaroxaban 울산의대 서울아산병원 심장내과 최기준
Practical Management of Patients receiving Rivaroxaban 울산의대 서울아산병원 심장내과 최기준 Contents Converting to/from rivaroxaban Measuring levels of rivaroxaban Patients potentially at higher risk of bleeding Renal
Antithrombotic therapy
Orthogeriatrics Clinical Summary Document Antithrombotic therapy Topics Preexisting anticoagulation and timing of surgery Reversal of anticoagulation Perioperative thromboprophylaxis When should we be
The Anti coagulated Patient: The Cardiologist s View. February 28, 2015
The Anti coagulated Patient: The Cardiologist s View February 28, 2015 Conflicts Dr. McMurtry has no conflicts to disclose. CanMeds Medical Expert (as Medical Experts, physicians integrate all of the CanMEDS
Guideline for managing patients on a factor Xa inhibitor Apixaban (Eliquis ) or Rivaroxaban (Xarelto )
Guideline [Optional heading here. Change font size to suit] Document Number # QH-GDL-950:2014-2 Guideline for managing patients on a factor Xa inhibitor Apixaban (Eliquis ) or Rivaroxaban (Xarelto ) 1.
DVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
Acute Ischemic Stroke with tpa
Admission/Condition/Diagnosis Admission: Admitting Physician Attending Physician Assign to Inpatient Status Transfer to Level of Care: Physician MUST document in notes the risk, severity, and skilled nursing